Financial reports
NT 10-K
Notice of late annual filing
18 Mar 24
NT 10-Q
Notice of late quarterly filing
9 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
10-K
2022 FY
Annual report
23 Mar 23
NT 10-K
Notice of late annual filing
17 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
Current reports
8-K
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Forward-Looking Statements Disclaimer
12 Apr 24
8-K
Departure of Directors or Certain Officers
8 Mar 24
8-K
Entry into a Material Definitive Agreement
1 Mar 24
8-K
Cost Associated with Exit or Disposal Activities
29 Feb 24
8-K
Other Events
13 Feb 24
8-K
Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio
18 Jan 24
8-K
Entry into a Material Definitive Agreement
16 Jan 24
8-K/A
Departure of Directors or Certain Officers
22 Dec 23
8-K
Results of Operations and Financial Condition
15 Dec 23
8-K
Regulation FD Disclosure
6 Dec 23
Registration and prospectus
S-3
Shelf registration
11 Oct 22
S-8
Registration of securities for employees
25 Mar 22
S-3
Shelf registration
15 Nov 19
S-8
Registration of securities for employees
18 Dec 18
S-8
Registration of securities for employees
20 Mar 17
D
$50.74M in equity, sold $2.74M, 2 investors
23 Nov 16
S-8
Registration of securities for employees
16 Sep 16
S-8
Registration of securities for employees
2 Sep 15
424B5
Prospectus supplement for primary offering
17 Mar 15
424B5
Prospectus supplement for primary offering
16 Mar 15
Proxies
DEFA14A
Additional proxy soliciting materials
1 May 23
DEF 14A
Definitive proxy
1 May 23
DEFA14A
Additional proxy soliciting materials
15 Jun 22
DEF 14A
Definitive proxy
15 Jun 22
DEFA14A
Additional proxy soliciting materials
30 Apr 21
DEF 14A
Definitive proxy
30 Apr 21
DEFA14A
Additional proxy soliciting materials
22 May 20
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEF 14A
Definitive proxy
29 Apr 20
DEFA14A
Additional proxy soliciting materials
30 Apr 19
Other
EFFECT
Notice of effectiveness
20 Oct 22
UPLOAD
Letter from SEC
17 Oct 22
CORRESP
Correspondence with SEC
17 Oct 22
SEC STAFF
SEC staff action: Order
16 Apr 21
SEC STAFF
SEC staff action: Order
19 Mar 21
UPLOAD
Letter from SEC
21 Feb 20
CORRESP
Correspondence with SEC
29 Jan 20
UPLOAD
Letter from SEC
23 Dec 19
EFFECT
Notice of effectiveness
17 Dec 19
CORRESP
Correspondence with SEC
12 Dec 19
Ownership
SC 13G/A
Tarriff Scott
18 Mar 24
4
Scott Tarriff
1 Mar 24
4
Brian Joseph Cahill
29 Feb 24
4
Scott Tarriff
29 Feb 24
SC 13D
Graves Michael
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
13 Feb 24
SC 13G
BRANDES INVESTMENT PARTNERS, LP
12 Feb 24
SC 13G
HIRSCHMAN ORIN
7 Feb 24
4
Brian Joseph Cahill
6 Feb 24